(Q35095351)

6 August 2017

Characterization of a novel glucokinase activator in rat and mouse models (English)

1 reference

6 August 2017

Pingping Li

2

0 references

author name string

Min Lu

1

1 reference

6 August 2017

Gautam Bandyopadhyay

3

1 reference

6 August 2017

William Lagakos

4

1 reference

6 August 2017

Walter E Dewolf

5

1 reference

6 August 2017

Taylor Alford

6

1 reference

6 August 2017

Mark Joseph Chicarelli

7

1 reference

6 August 2017

Lance Williams

8

1 reference

6 August 2017

Deborah A Anderson

9

1 reference

6 August 2017

Brian R Baer

10

1 reference

6 August 2017

Maralee McVean

11

1 reference

6 August 2017

Marion Conn

12

1 reference

6 August 2017

Murielle M Véniant

13

1 reference

6 August 2017

Peter Coward

14

1 reference

6 August 2017

language of work or name

English

0 references

publication date

12 February 2014

1 reference

6 August 2017

1 reference

6 August 2017

9

1 reference

6 August 2017

2

1 reference

6 August 2017

e88431

1 reference

Creative Commons Attribution 4.0 International

6 August 2017

start time

12 February 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922816

Chronic treatment with a glucokinase activator delays the onset of hyperglycaemia and preserves beta cell mass in the Zucker diabetic fatty rat.

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922816

Metabolic disease drug discovery- "hitting the target" is easier said than done

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922816

Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922816

Glucokinase activators for diabetes therapy: May 2010 status report

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922816

A new antidiabetic compound attenuates inflammation and insulin resistance in Zucker diabetic fatty rats

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922816

Assessing the potential of glucokinase activators in diabetes therapy

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922816

Insulin sensitivity: modulation by nutrients and inflammation

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922816

The common P446L polymorphism in GCKR inversely modulates fasting glucose and triglyceride levels and reduces type 2 diabetes risk in the DESIR prospective general French population

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922816

Glucokinase activator PSN-GK1 displays enhanced antihyperglycaemic and insulinotropic actions

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922816

Mechanisms of beta-cell death in type 2 diabetes.

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922816

The Cellular Fate of Glucose and Its Relevance in Type 2 Diabetes

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922816

Insights into the biochemical and genetic basis of glucokinase activation from naturally occurring hypoglycemia mutations

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922816

Familial hyperinsulinism caused by an activating glucokinase mutation

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922816

Combined therapy with insulin plus oral agents: is there any advantage? An argument in favor

28 July 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0088431

Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0088431

Metabolic impact of glucokinase overexpression in liver: lowering of blood glucose in fed rats is accompanied by hyperlipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0088431

Allosteric activators of glucokinase: potential role in diabetes therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0088431

Pharmacokinetic and pharmacodynamic properties of the glucokinase activator MK-0941 in rodent models of type 2 diabetes and healthy dogs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0088431

Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0088431

Hepatic glucokinase expression is associated with lipogenesis and fatty liver in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0088431

Severe persistent hyperinsulinemic hypoglycemia due to a de novo glucokinase mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0088431

Glucokinase gene locus transgenic mice are resistant to the development of obesity-induced type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0088431

Hepatic glucokinase modulates obesity predisposition by regulating BAT thermogenesis via neural signals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0088431

Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922816

Characterization of glucokinase mutations associated with maturity-onset diabetes of the young type 2 (MODY-2): different glucokinase defects lead to a common phenotype

27 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24533087

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1371/JOURNAL.PONE.0088431

1 reference

6 August 2017

0 references

1 reference

6 August 2017

1 reference